Expression of basal and luminal cytokeratins in breast cancer and their correlation with clinicopathological prognostic variables

Mohammadizadeh, Fereshteh; Naimi, Azar; Rajabi, Parvin; Basir, Hamid Reza Ghasemi; Eftekhari, Ali

doi:10.4103/0019-5359.50764

Cited by 9 publications

(6 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(p=0.021) which is similar to observations reported by Huang et al [18] and Singhai et al [19] in their studies and reported that lymph node metastasis showed an increasing trend with increase in tumour grade respectively. CK 5/6 expression was noted in 40% cases of triple negative breast carcinoma These findings corroborated with results from studies by Mohammadizadeh et al [16] and Yadav et al [20] , reporting CK 5/6 positivity in TNBC as 47.8% and 59% cases respectively. Similar observations were also recorded by Sutton et al [21] and Pintens et al [22] in their respective studies observing CK 5/6 positivity in TNBC cases to be 62% and 60% respectively No significant association was found between CK 5/6 expression and the size of tumour.…”

Section: Discussionsupporting

confidence: 90%

See 1 more Smart Citation

To study the expression of cytokeratin 5 and 6 in triple negative breast carcinoma: An immunohistochemical study

Rattan¹,

Шарма²,

Kaur³

et al. 2023

Int. J. Clin. Diagn. Pathol.

View full text Add to dashboard Cite

Introduction: Breast cancer is the second most common cancer developing in women worldwide Triple Negative Breast Carcinomas (TNBC) are regarded as one of the most malignant phenotypes, Immunohisto-chemically these tumors are endocrine receptor negative, HER2 -receptor negative, with expression of basal markers -Cytokeratin 5 /6, carrying a poor prognosis. Effective evaluation of these tumor markers helps in efficient treatment of the patient with all these markers carrying a prognostic significance. The current study helps in identifying Cytokeratin 5/6 as a potential multifaceted biomarker and in identifying novel therapeutic agents for Triple Negative Breast Carcinomas. Materials and Methods:The present immunohistochemical study was conducted on 40 histologically proven cases of triple negative breast carcinoma (TNBC) which were further subjected to Cytokeratin 5/6 expression to determine prognostic and therapeutic value. Result: Cytokeratin 5/6 expression was seen in 16 cases of TNBC, out of 40 histologically proven cases of TNBC. The maximum number of patients of triple negative breast carcinoma were in the age group of 41-50 years comprising 40% of the total cases. % of the total cases. Maximum number of cases of triple negative breast carcinoma were of grade III, constituting 60% followed by grade II Conclusion: According to the current study, Cytokeratin 5/6 positivity has got direct relationship with the grade of the tumour, lymph nodal status and lymphovascular invasion in TNBC cases. TNBC have a grave clinical outcome and decreased 5 year survival rate. Thus, it is highlighted that all TNBC patients should be stained by CK 5/6 and if found positive for CK 5/6 expression it, implies basal like phenotype and aggressive intervention is required. Cytokeratin 5/6 carries a diagnostic as wells as therapeutic importance.

show abstract

Section: Discussionsupporting

confidence: 90%

“…Axillary lymph node metastasis was seen in 65% cases. Similar trends were seen in studies done by Mohammadizadeh et al, [16] ; Suhani et al [17] who reported involvement of lymph node metastasis in 73% and 59.2% cases. In present study no definite correlation between tumour size and lymph node status was observed.…”

Section: Discussionsupporting

confidence: 89%

To study the expression of cytokeratin 5 and 6 in triple negative breast carcinoma: An immunohistochemical study

Rattan¹,

Шарма²,

Kaur³

et al. 2023

Int. J. Clin. Diagn. Pathol.

View full text Add to dashboard Cite

show abstract

“…Despite semi-quantitative results and susceptibility to both inter-observer and technical variation—short comings which can be remedied to some extent through sufficient training and implementation of stringent protocols—immunohistochemistry is suited for application on formalin-fixed paraffin-embedded samples and also provides the unique advantage of simultaneous morphological analysis. In fact, few published reports on basal-like breast cancer have used a gene expression profile gold standard, opting instead to use immunohistochemistry-based methodologies while investigating this subtype primarily due to cost, but also to avoid the complex sample preparation and data analysis processes [ 5 , 30 ].…”

Section: Biomarker Panels For Basal-like Breast Cancermentioning

confidence: 99%

Biomarkers for Basal-like Breast Cancer

Choo

Nielsen

2010

Cancers

View full text Add to dashboard Cite

Initially recognized through microarray-based gene expression profiling, basal-like breast cancer, for which we lack effective targeted therapies, is an aggressive form of carcinoma with a predilection for younger women. With some success, immunohistochemical studies have attempted to reproduce the expression profile classification of breast cancer through identification of subtype-specific biomarkers. This review aims to present an in depth summary and analysis of the current status of basal-like breast cancer biomarker research. While a number of biomarkers show promise for future clinical application, the next logical step is a comprehensive investigation of all biomarkers against a gene expression profile gold standard for breast cancer subtype assignment.

show abstract

“…Moreover recent reports suggest that interactions between keratins and other proteins modulate signaling cascades that regulate cell migration, invasion, and metastasis. According to this suggestion several cytokeratins were found differently expressed in malignant epithelial cells, their specific expression pattern frequently correlated with the prognosis and metastatic potential of certain tumors, like in breast cancer and tumors of the oral cavity [ 24 – 25 ]. KRT1 is coexpressed with KRT10 in the suprabasal layer of the epidermis, elevated expression of the KRT1/KRT10 complex indicate increased terminal differentiation of keratinocytes.…”

Section: Discussionmentioning

confidence: 99%

Analysis of KRT1, KRT10, KRT19, TP53 and MMP9 expression in pediatric and adult cholesteatoma

et al. 2018

View full text Add to dashboard Cite

Cholesteatoma is an epidermal cyst with still unknown pathomechanism. The aim of the current study was to investigate molecular differences in the background of the hyperproliferative property and aggressive behavior typical of the cholesteatoma epithelium. The expression of three cytokeratin genes (KRT1, KRT10 and KRT19), the matrix metalloproteinase 9 gene (MMP9) and the tumor suppressor TP53 gene was measured by qRT-PCR in surgical samples of pediatric and adult cholesteatoma cases and their expression level was compared to that of normal skin samples from the retroauricular region of control individuals. Cholesteatoma samples were stratified according to the age of onset and recurrence for more detailed analysis. Our results showed identical expression pattern for KRT1 and KRT10, their expression was higher in pediatric cases than in adults, especially in pediatric recurrent samples. The expression level of KRT19 was inversely proportional to that of KRT1/KRT10, it was lower in the more invasive recurrent cases both in our pediatric and adult groups. As it was expected from the bone destructive behavior of cholesteatoma, a significantly elevated expression of MMP9 was measured in cholesteatoma samples, the highest level was found in adult recurrent cases. Low expression levels characterize the TP53 gene without significant differences in our samples. These findings demonstrate that cytokeratin expression distinguishes between pediatric/adult, nonrecurrent/recurrent cases, suggesting that distinct differentiation state and cell division potential characterize these cholesteatoma cases. KRT19 with a tumor suppressor potential might restrict the recurrence of cholesteatoma. The differences observed in gene expression profiles between cholesteatoma and control samples support the notion that cholesteatoma is a cystic lesion with tumor-like behavior because it is characterized by invasive, destructive growth and high tendency for recurrence.

show abstract

Expression of basal and luminal cytokeratins in breast cancer and their correlation with clinicopathological prognostic variables

Cited by 9 publications

References 26 publications

To study the expression of cytokeratin 5 and 6 in triple negative breast carcinoma: An immunohistochemical study

To study the expression of cytokeratin 5 and 6 in triple negative breast carcinoma: An immunohistochemical study

Biomarkers for Basal-like Breast Cancer

Analysis of KRT1, KRT10, KRT19, TP53 and MMP9 expression in pediatric and adult cholesteatoma

Contact Info

Product

Resources

About